{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:44:53Z","timestamp":1750743893794,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["ChiCTR-OIC-17012883"],"award-info":[{"award-number":["ChiCTR-OIC-17012883"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10147-021-01898-9","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T09:07:57Z","timestamp":1616404077000},"page":"1091-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Qiaoyan","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangfang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"10","key":"1898_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","volume":"12","author":"A Glaus","year":"2004","unstructured":"Glaus A, Knipping C, Morant R et al (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12(10):708\u2013715","journal-title":"Support Care Cancer"},{"issue":"2","key":"1898_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","volume":"8","author":"FM Schnell","year":"2003","unstructured":"Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8(2):187\u2013198","journal-title":"Oncologist"},{"key":"1898_CR3","unstructured":"National Comprehensive Cancer Networks (2019) NCCN Clinical practice guidelines in oncology: colon cancer (Version 2.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 15 May 2019"},{"key":"1898_CR4","unstructured":"National Comprehensive Cancer Networks (2019) NCCN Clinical Practice Guidelines in oncology: rectal Cancer (Version 2.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed 15 May 2019"},{"key":"1898_CR5","unstructured":"National Comprehensive Cancer Networks (2019) NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (Version 2.2019).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf. Accessed 3 June 2019"},{"key":"1898_CR6","unstructured":"National Comprehensive Cancer Networks (2020) NCCN Clinical Practice Guidelines in Oncology: Antiemesis(Version1.2020).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 19 Feb 2020"},{"issue":"28","key":"1898_CR7","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35(28):3240\u20133261","journal-title":"J Clin Oncol"},{"issue":"1","key":"1898_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25(1):303\u2013308","journal-title":"Support Care Cancer"},{"key":"1898_CR9","doi-asserted-by":"crossref","unstructured":"Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int, pp 1\u20136.","DOI":"10.1155\/2015\/595894"},{"issue":"1","key":"1898_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ctrv.2012.09.002","volume":"39","author":"MS Aapro","year":"2013","unstructured":"Aapro MS, Schmoll HJ, Jahn F et al (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 39(1):113\u2013117","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1898_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00434947","volume":"1","author":"CM Lindley","year":"1992","unstructured":"Lindley CM, Hirsch JD, O\u2019Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1(5):331\u2013340","journal-title":"Qual Life Res"},{"issue":"3","key":"1898_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","volume":"113","author":"W Yeo","year":"2009","unstructured":"Yeo W, Mo FKF, Suen JJS et al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529\u2013535","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11(8):522\u2013527","journal-title":"Support Care Cancer"},{"issue":"4","key":"1898_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431","journal-title":"Support Care Cancer"},{"issue":"7","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","volume":"20","author":"PJ Hesketh","year":"2012","unstructured":"Hesketh PJ, Wright O, Rosati G et al (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 20(7):1471\u20131478","journal-title":"Support Care Cancer"},{"issue":"12","key":"1898_CR16","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830","journal-title":"J Clin Oncol"},{"issue":"6","key":"1898_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 21(6):1655\u20131663","journal-title":"Support Care Cancer."},{"issue":"2","key":"1898_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28(1):131","journal-title":"J Exp Clin Cancer Res"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2016.01.015","volume":"58","author":"A Llombart-Cussac","year":"2016","unstructured":"Llombart-Cussac A, Ramos M, Dalmau E et al (2016) Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group\/2009\u201302 study. Eur J Cancer. 58:122\u2013129","journal-title":"Eur J Cancer."},{"issue":"3","key":"1898_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10147-016-1081-y","volume":"22","author":"T Inoue","year":"2017","unstructured":"Inoue T, Kimura M, Uchida J et al (2017) Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Int J Clin Oncol 22(3):600\u2013604","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"1898_CR22","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00520-011-1345-z","volume":"20","author":"CE Wu","year":"2012","unstructured":"Wu CE, Liaw CC (2012) Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Support Care Cancer 20(10):2357\u20132361","journal-title":"Support Care Cancer"},{"issue":"8","key":"1898_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00520-008-0545-7","volume":"17","author":"PJ Hesketh","year":"2009","unstructured":"Hesketh PJ, Younger J, Sanz-Altamira P et al (2009) Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 17(8):1065\u20131070","journal-title":"Support Care Cancer"},{"issue":"10","key":"1898_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51(10):1274\u20131282","journal-title":"Eur J Cancer"},{"key":"1898_CR25","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.2147\/OTT.S158570","volume":"11","author":"RM Navari","year":"2018","unstructured":"Navari RM, Schwartzberg LS (2018) Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Therapy 11:6459\u20136478","journal-title":"OncoTargets Therapy"},{"issue":"3","key":"1898_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21(3):491\u2013497","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"1898_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0959-8049(03)00299-5","volume":"39","author":"AR Martin","year":"2003","unstructured":"Martin AR, Carides AD, Pearson JD et al (2003) Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomized study of the NK-1 antagonist aprepitant. Eur J Cancer 39(10):1395\u20131401","journal-title":"Eur J Cancer"},{"issue":"2\u20133","key":"1898_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","volume":"28","author":"A du Bois","year":"1992","unstructured":"du Bois A, Meerpohl HG, Vach W et al (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin pretreated patients: a study with ondansetron. Eur J Cancer 28(2\u20133):450\u2013457","journal-title":"Eur J Cancer"},{"issue":"6","key":"1898_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104(6):711\u2013717","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01898-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-01898-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01898-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T09:18:31Z","timestamp":1621415911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-01898-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01898-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest associated with this work. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}